Pfizer’s Viagra Going Generic: Cheaper Options Coming Soon

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Source: AMC

Pfizer Inc. (NYSE:PFE) is known for many things, clinical drug trials, research, development, manufacturing, and sales in fields that range from oncology to animal health. However, possibly one of its more well known discoveries — especially if you’re of the dangling participle persuasion — is the company’s solution to erectile dysfunction — Viagra.

Now, the medication is set to go generic, with Teva (NYSE:TEVA) coming to an agreement with Pfizer that will allow it to begin selling generic variants, according to Bloomberg. The agreement has Teva paying Pfizer patent royalties until April of 2020, and Teva can start putting their versions on the market in 2017 — though in Europe it had already begun efforts.

“This blue pill changed the way we practiced medicine,” David Samadi, Chair of urology at Lenox Hill Hospital, told Bloomberg. In 2012 alone, Viagra brought in $2.05 billion in revenue — not bad for a drug discovered by accident. It may not be the solution to high blood pressure Pfizer was looking for, but millions of Americans aren’t complaining.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business